General
Preferred name
ARTEMISININ
Synonyms
NSC 369397 ()
Qinghaosu ()
Qinghaosu,Artemisinine ()
Artemisinine ()
Qinghaosu,Artemisinine,Coartem,NSC 369397 ()
Artemisinin-d3 ()
P&D ID
PD012296
CAS
63968-64-9
176652-07-6
Tags
available
natural product
drug
Drug indication
Malaria
Drug Status
investigational
approved
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Artemisinin is a sesquiterpene lactone with an unusual endoperoxide bridge, believed to be responsible for the antimalarial activity of the compound. It is a natural product, isolated from the quinghaosu or sweet wormwood plant (Artemisia annua) and used in Chinese traditional medicine to treat fever.
Artemisinin is a prodrug that is converted to the active metabolite (dihydroartemisinin). A number of semisynthetic artemisinin derivatives have been developed that have an improved pharmacokinetic profile, these include , , and .
Artemisinin and derivatives have potent activity against the asexual blood stage of P. falciparum (including chloroquine-resistant strains) and are characterised by an extremely rapid parasitemia clearance and a short terminal half-life of elimination. Combination therapies, containing an artemisinin derivative (artemisinin-combination therapies, ACTs), are recommended by the World Health Organization as the standard treatment for uncomplicated P. falciparum malaria .
We show one representation of artemisinin here. As with other natural products, there are alternative chemical structures due to the complex stereochemistry.
Potential Target/Mechanism Of Action: As the precise mechanism of action of artemisinin is not yet known, we do not have a molecular target for this compound.
Artemisinin is a prodrug that is converted to the active metabolite (dihydroartemisinin). A number of semisynthetic artemisinin derivatives have been developed that have an improved pharmacokinetic profile, these include , , and .
Artemisinin and derivatives have potent activity against the asexual blood stage of P. falciparum (including chloroquine-resistant strains) and are characterised by an extremely rapid parasitemia clearance and a short terminal half-life of elimination. Combination therapies, containing an artemisinin derivative (artemisinin-combination therapies, ACTs), are recommended by the World Health Organization as the standard treatment for uncomplicated P. falciparum malaria .
We show one representation of artemisinin here. As with other natural products, there are alternative chemical structures due to the complex stereochemistry.
Potential Target/Mechanism Of Action: As the precise mechanism of action of artemisinin is not yet known, we do not have a molecular target for this compound.
DESCRIPTION
Artemisinin is a sesquiterpene lactone with an unusual endoperoxide bridge, believed to be responsible for the antimalarial activity of the compound. It is a natural product, isolated from the qinghao or sweet wormwood plant (Artemisia annua) and used in Chinese traditional medicine to treat fever.
Artemisinin is a prodrug that is converted to the active metabolite (dihydroartemisinin).
We show one representation of artemisinin here. As with other natural products, there are alternative chemical structures due to the complex stereochemistry.
The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. (GtoPdb)
Artemisinin is a prodrug that is converted to the active metabolite (dihydroartemisinin).
We show one representation of artemisinin here. As with other natural products, there are alternative chemical structures due to the complex stereochemistry.
The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. (GtoPdb)
DESCRIPTION
Glucosidase alpha inhibitor (intestinal)
(Tocris Bioactive Compound Library)
DESCRIPTION
Antimalarial; inhibits P-type ATPase (PfATP6) of P.falciparum
(Tocriscreen Plus)
DESCRIPTION
Antimalarial; inhibits P-type ATPase (PfATP6) of P. falciparum
(Tocriscreen Total)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
19
Organisms
7
Compound Sets
18
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
Tocriscreen Plus
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
39
Molecular Weight
282.15
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
0
Rotatable Bonds
0
Ring Count
5
Aromatic Ring Count
0
cLogP
2.39
TPSA
53.99
Fraction CSP3
0.93
Chiral centers
7.0
Largest ring
7.0
QED
0.5
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzymes
Pathway
Microbiology&virology
Anti-infection
Apoptosis
PI3K/Akt/mTOR
Target
HCV
Parasite
CYP2B6
Akt
Ferroptosis
ADC Cytotoxin,Anti-infection
Primary Target
Ca2+-ATPase
MOA
HCV Protease
Inhibitor
DNA synthesis inhibitor
Indication
malaria
Biosynthetic Origin
Terpenoid
Therapeutic Indication
Antiparasitic
Therapeutic Class
Antimicrobial
Source data
